Chemotherapy Versus Chemoradiation as Preoperative Therapy for Resectable Pancreatic Ductal Adenocarcinoma: A Propensity Score Adjusted Analysis. Issue 2 (February 2019)
- Record Type:
- Journal Article
- Title:
- Chemotherapy Versus Chemoradiation as Preoperative Therapy for Resectable Pancreatic Ductal Adenocarcinoma: A Propensity Score Adjusted Analysis. Issue 2 (February 2019)
- Main Title:
- Chemotherapy Versus Chemoradiation as Preoperative Therapy for Resectable Pancreatic Ductal Adenocarcinoma
- Authors:
- Cloyd, Jordan M.
Chen, Hsiang-Chun
Wang, Xuemei
Tzeng, Ching-Wei D.
Kim, Michael P.
Aloia, Thomas A.
Vauthey, Jean-Nicolas
Lee, Jeffrey E.
Katz, Matthew H.G. - Abstract:
- Abstract : Objectives: Although the use of neoadjuvant therapy for resectable pancreatic ductal adenocarcinoma is increasing, the optimal preoperative treatment regimen remains poorly defined. Methods: All patients with resectable pancreatic ductal adenocarcinoma who received preoperative chemotherapy alone (12%) or chemoradiation therapy (CRT) alone (88%) before pancreatectomy between 1999 and 2014 were included. Propensity score matching with inverse probability weighting was conducted based on age, baseline carbohydrate antigen 19-9, and procedure type. Results: Patients who received preoperative CRT were more likely to undergo a margin negative (91% vs 79%, P < 0.01) and node negative (53% vs 23%, P < 0.01) resection and experience less locoregional recurrence (LR; 16% vs 33%, P < 0.01) but similar median overall survival (OS; 33.6 vs 26.4 months, P = 0.09). On multivariate analysis, carbohydrate antigen 19-9 (hazard ratio, 1.2; 95% confidence interval [CI], 1.1–1.3) and positive lymph nodes (hazard ratio, 1.5; 95% CI, 1.0–2.2) were associated with OS, whereas tumor size (odds ratio [OR], 1.5; 95% CI, 1.3–1.8), positive lymph nodes (OR, 3.1; 95% CI, 1.8–5.6), and preoperative chemotherapy (OR, 1.8; 95% CI, 1.1–2.9) were associated with LR. Conclusions: Preoperative CRT is associated with less margin and lymph node positivity, reduced LR, and similar OS compared with preoperative chemotherapy.
- Is Part Of:
- Pancreas. Volume 48:Issue 2(2019)
- Journal:
- Pancreas
- Issue:
- Volume 48:Issue 2(2019)
- Issue Display:
- Volume 48, Issue 2 (2019)
- Year:
- 2019
- Volume:
- 48
- Issue:
- 2
- Issue Sort Value:
- 2019-0048-0002-0000
- Page Start:
- Page End:
- Publication Date:
- 2019-02
- Subjects:
- pancreas cancer -- neoadjuvant therapy -- FOLFIRINOX -- whipple -- pancreatectomy
Pancreas -- Diseases -- Periodicals
Pancreas -- Periodicals
Neuroendocrine tumors -- Periodicals
616.37005 - Journal URLs:
- http://ovidsp.ovid.com/ovidweb.cgi?T=JS&NEWS=n&CSC=Y&PAGE=toc&D=yrovft&AN=00006676-000000000-00000 ↗
http://www.pancreasjournal.com ↗
http://journals.lww.com/pancreasjournal/pages/default.aspx ↗
http://journals.lww.com ↗ - DOI:
- 10.1097/MPA.0000000000001231 ↗
- Languages:
- English
- ISSNs:
- 0885-3177
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 6357.351500
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 11601.xml